Quick Answer
Corbus Pharmaceuticals Holdings, Inc. reported Earnings Per Share Diluted of $5.90 (loss) per share for the year ending 2025.
- Corbus Pharmaceuticals Holdings, Inc. showed a decrease of -60.3% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Corbus Pharmaceuticals Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $0.21 (loss) per share | Q2 2019: $0.03 per share | Q2 2020: $0.52 (loss) per share | Q3 2021: $0.02 (loss) per share | Q1 2022: $2.26 (loss) per share | Q2 2022: $3.18 (loss) per share | Q3 2022: $2.11 (loss) per share | Q1 2023: $4.24 (loss) per share | Q2 2023: $2.05 (loss) per share | Q3 2023: $2.27 (loss) per share | Q1 2024: $0.83 (loss) per share | Q2 2024: $0.90 (loss) per share | Q3 2024: $1.15 (loss) per share | Q1 2025: $1.39 (loss) per share | Q2 2025: $1.44 (loss) per share | Q3 2025: $1.90 (loss) per share.
- Over the full 5 years of available data (2021 to 2025), Corbus Pharmaceuticals Holdings, Inc.'s Earnings Per Share Diluted has grown by 47.1%.
- Historical annual values: Fiscal year 2025: $5.90 (loss) per share | Fiscal year 2024: $3.68 (loss) per share | Fiscal year 2023: $10.31 (loss) per share | Fiscal year 2022: $10.15 (loss) per share | Fiscal year 2021: $11.15 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: